Skip to main content

Clinic of infectious diseases

The objective of the infectious diseases clinic at the Institut Jules Bordet is to prevent and treat the infectious complications occurring in cancer patients, whether they are connected with the cancer itself or with its treatment (chemotherapy, radiotherapy, surgery, etc.)

Research projects


  

Project 1

Role of monitoring smears in detecting patients colonised with resistant bacteria in neutropenic patients and their impact on empirical treatments in the case of febrile neutropenia.

Project 2

Epidemiology of invasive fungal infections

Projet 3 

Fever of undetermined origin: role of PETscan

Our team

Head of Clinic
Dr Mickael Aoun
(Secretary : Nathalie Cardinal)

Team
Dr Aspasia Georgala
Dr Angela Loizidou
Vanessa Coubeaux (research nurse)

 Scientific publications

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.

Authors : Sidibe FM, Traore Z, Georgala A, Kanab R, Larsimont D, Awada A, Piccart-Gebhart M
Year : 2018
Journal : Bull Cancer
Volume : 105
Pages : 842-846

Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.

Authors : Maertens J, Selleslag D, Heinz WJ, Saulay M, Rahav G, Giladi M, Aoun M, Kovanda L, Kaufhold A, Engelhardt M, Cornely OA, Herbrecht R, Ullmann AJ
Year : 2018
Journal : Mycoses
Volume : 61
Pages : 868-876

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Authors : Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J
Year : 2017
Journal : J Antimicrob Chemother
Volume : 72(12)
Pages : 3406-3413

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Authors : Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ
Year : 2016
Journal : Lancet
Volume : 387(10020)
Pages : 760-9

Fever of unknown origin in cancer patients.

Authors : Loizidou A, Aoun M, Klastersky J
Year : 2016
Journal : Crit Rev Oncol Hematol
Volume : 101
Pages : 125-30

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more